 |
 |
 |
 |
 |
 |
|
 |
 |
 |
LEADERSHIP COMPANY OVERVIEW BOARD OF DIRECTORS WEB BASED RESOURCES SCIENTIFIC ADVISORY BOARD |
 |
Company Overview Javelin is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. Javelin’s product candidates address the acute moderate-to-severe pain medication market segment. We are developing differentiated pain control products that provide the flexibility and versatility required to address the limitations of existing prescription pain medications in supervised health care settings. Indications under development include post-operative pain, orthopedic injury pain, procedural pain, burn pain and trauma. Our products and product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments. Javelin has one marketed product - Dyloject® - in the United Kingdom. In the United States, the company has submitted a New Drug Application (NDA) for Dyloject™ and has two drug candidates in US Phase III clinical development: Ereska™ (intranasal ketamine) and Rylomine™ (intranasal morphine). |
|
